Seliciclib in malignancies (Q43235605)

16 November 2017

Seliciclib in malignancies (English)

1 reference

16 November 2017

3

1 reference

16 November 2017

Ibrahim T Aldoss

1

1 reference

PubMed ID

19938906

16 November 2017

Tsewang Tashi

series ordinal

2

1 reference

PubMed ID

19938906

16 November 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Expert Opinion on Investigational Drugs

16 November 2017

1 reference

16 November 2017

18

1 reference

16 November 2017

12

1 reference

16 November 2017

1957-1965

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

16 November 2017

1 reference

Principles of CDK regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Mammalian cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Cell cycle, CDKs and cancer: a changing paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

G1 phase progression: cycling on cue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

21 January 2018

Cyclin-Dependent Kinases

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Cyclin D-dependent kinases, INK4 inhibitors and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Cyclin D1 in breast cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

To cycle or not to cycle: a critical decision in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Cyclin-dependent kinase pathways as targets for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

A p34(cdc2) survival checkpoint in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Inhibition of cyclin-dependent kinases by purine analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Specific protection against breast cancers by cyclin D1 ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients' pretreatment status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

Stability, pKa and plasma protein binding of roscovitine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903418445

10.1517/13543780903418445

21 January 2018

Identifiers

DOI

1 reference

16 November 2017

1 reference

PubMed ID

19938906